BMY vs EWTX: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
BMY is the larger of the two ($133.41B market cap): the incumbent the market prices for continued execution (10.10x forward earnings, beta 0.23). EWTX is the smaller challenger ($4.13B), priced similarly on forward earnings (-26.09x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
BMY vs EWTX: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BMY | EWTX | What it tells you |
|---|---|---|---|
| Market cap | $133.41B | $4.13B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 10.10 | -26.09 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.23 | 0.28 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 98% of range | 72% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 5.98 | 8.37 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how BMY and EWTX affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMY and EWTX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMY and EWTX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Bristol Myers Squibb (BMY) do?
Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is navigating a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.
What does Edgewise Therapeutics (EWTX) do?
Edgewise Therapeutics (Nasdaq: EWTX) is a Boulder, Colorado clinical-stage biopharmaceutical company developing orally administered small molecules that target muscle for rare neuromuscular and serious cardiac conditions. Its lead candidate, sevasemten (formerly EDG-5506), is a skeletal myosin inhibitor in late-stage trials for Becker and Duchenne muscular dystrophy, with the global pivotal GRAND CANYON cohort in Becker due to read out top-line results in the fourth quarter of 2026 and a planned FDA New Drug Application submission in the first half of 2027. A second program, EDG-7500, is a cardiac sarcomere modulator that posted positive 12-week Phase 2 CIRRUS-HCM data in obstructive and nonobstructive hypertrophic cardiomyopathy in mid-2026, with a Phase 3 program targeted to begin in the second half of 2026.
BMY vs EWTX: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- BMY drivers: New product portfolio ramp; Oncology and immunology depth.
- EWTX drivers: Sevasemten in Becker muscular dystrophy; EDG-7500 in hypertrophic cardiomyopathy.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. For EWTX, as a pre-revenue clinical-stage biotech, Edgewise has no approved products and its value depends on binary trial outcomes that can move the stock violently in either direction.
BMY or EWTX: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BMY if you believe its drivers more; EWTX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMY and EWTX guides.
BMY vs EWTX: the full fundamentals
BMY. Bristol Myers tends to trade at a low forward earnings multiple relative to large-cap pharma peers, reflecting market skepticism about its ability to replace patent-cliff revenue. The high dividend yield and strong free cash flow are the bull-case anchors, while the depressed valuation reflects the bear case that legacy declines outrun newer products.
EWTX. Edgewise generates no product revenue, so traditional valuation multiples do not apply and the stock trades on the expected value of its pipeline. The roughly $499.6 million cash position against a quarterly burn near $50 million supports a runway of several years past the key Becker readout. The multi-billion-dollar market capitalization reflects investor expectations for sevasemten and EDG-7500 rather than any current financial performance.
Headline figures (approximate, early 2026): BMY shows revenue (ttm) ~$48 billion, operating margin ~20% (varies with acquisition charges), net income (ttm) volatile, pressured by large acquisition write-offs, dividend yield ~4-5%; EWTX shows product revenue ~$0 (pre-commercial), cash & marketable securities ~$499.6M, net loss (q1 2026) ~$49.0M, net loss per share (q1 2026) ~$0.46.
The bottom line: BMY vs EWTX
BMY and EWTX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BMY and EWTX exposure against your real portfolio. It is not an investment adviser.
Wondering how BMY or EWTX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Bristol Myers Squibb with AI
Connect the broker you already use and ask Walnut's AI how BMY fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between BMY and EWTX?
+
Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. Edgewise Therapeutics (Nasdaq: EWTX) is a Boulder, Colorado clinical-stage biopharmaceutical company developing orally administered small molecules that target muscle for rare neuromuscular and serious cardiac conditions. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BMY or EWTX the better stock?
+
Neither is universally better. BMY is the larger incumbent; EWTX is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BMY or EWTX?
+
On forward P/E (as of August 2026), BMY trades at 10.10x and EWTX at -26.09x, so EWTX is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BMY and EWTX?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BMY vs EWTX?
+
BMY: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. Revlimid has already declined under generic entry. The newer portfolio must scale fast enough to offset these losses, which is not guaranteed. Drug pricing pressure (including US Medicare negotiation under the Inflation Reduction Act, which named Eliquis), clinical trial failures, regulatory setbacks, and integration risk from large acquisitions all weigh on the outlook. High debt from dealmaking and litigation exposure add further uncertainty. EWTX: As a pre-revenue clinical-stage biotech, Edgewise has no approved products and its value depends on binary trial outcomes that can move the stock violently in either direction. A disappointing GRAND CANYON readout or a regulatory setback for sevasemten would remove a large share of the company's expected value. The HCM field is crowded with better-capitalized rivals, so EDG-7500 must show a genuinely differentiated safety and efficacy profile to matter commercially. The company continues to post net losses and will eventually need commercial success or further financing, which could dilute shareholders, and rare-disease trials carry meaningful enrollment, endpoint, and approval uncertainty.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BMY or EWTX; figures are approximate and dated (as of August 2026). Verify current data before investing.